Graduated from the University of Milan in Medicine and Surgery, and subsequently specialized in Cardiovascular Diseases and Sports Medicine. Until 2009 he worked at the Monzino Cardiology Center in Milan, dealing with heart failure, pulmonary hypertension and physiopathology of exercise. In 2009 he moved to the Maugeri Institute in Milan where he directs the Rehabilitation Cardiology Unit. Here he continues to deal with exercise and specific rehabilitation programs for various cardiorespiratory pathologies.

Dr Tiziana Bachetti is currently assistant to the Scientific Director at Istituti Clinici Scientifici Maugeri, an Italian research and care hospital, where she is responsible for the management of scientific aspects related to institutional basic, translational, and clinical research projects. She received a Masters of Sciences degree in Pharmacy in 1987 and completed her post-graduate training in Molecular Pharmacology at University of Bologna, Italy, in 1991. Her first research interests were in the field of Neuropharmacology and Vascular Pharmacology. She was then a post-doc in the Department of Clinical Pharmacology and Therapeutics at University College London, UK (2007-2008). Through the years, she has developed a broad interest in Cardiovascular Science actively participating in projects spanning from basic to clinical science. The focus of her research has always been on elucidating pathophysiological mechanisms of disease to identify suitable drug targets with special reference to endothelial dysfunction, heart failure, immune activation in cardiovascular diseases, and genetic channellopathies associated with sudden cardiac death. She is (co)author of more than 80 publications (Orcid ID: 0000-0003-1612-5329) and has a Scopus H index of 22 (Scopus Author ID: 7004334375).

Given her long-standing interests in angiotensin-converting enzyme and endothelial function, she enthusiastically joined the GEN-COVID study to give her contribution, together with the group headed by Prof Alessandra Renieri, to understand the impact of host genome on COVID-19 clinical variability.